A phase I, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ADCT-601 in patients with advanced solid tumours

被引：0
|
作者：
Tolcher, A. W. [1 ]
Falchook, G. [2 ]
Bendell, J. C. [3 ]
Ungar, D. [4 ]
Boni, J. [4 ]
Chao, G. [4 ]
Patel, M. R. [3 ,5 ]
机构：
[1] NEXT Oncol, Clin Res, San Antonio, TX USA
[2] HealthONE, Drug Dev Program, Sarah Cannon Res Inst, Denver, CO USA
[3] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[4] ADC Therapeut Inc, Clin Dev, Murray Hill, NJ USA
[5] Florida Canc Specialists, Sarasota Drug Dev Unit, Sarasota, FL USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
468P
引用
收藏
页码：176 / +
页数：2
相关论文
共 50 条
  • [1] Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
    Wu, Y.
    Jing, H.
    Zhang, J.
    Cao, X.
    Li, K.
    Liu, Y.
    Meng, M.
    Li, H.
    Kang, W.
    Li, J.
    Wang, Q.
    Zhu, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1497 - S1497
  • [2] The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study
    Yonemori, Kan
    Shimizu, Toshio
    Kondo, Shunsuke
    Iwasa, Satoru
    Koyama, Takafumi
    Kitano, Shigehisa
    Sato, Jun
    Shimomura, Akihiko
    Shibaki, Ryota
    Suri, Ajit
    Kase, Yoichi
    Sumino, Shuuji
    Tamura, Kenji
    Yamamoto, Noboru
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (05) : 693 - 699
  • [3] Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors
    Bendell, Johanna C.
    Patel, Manish R.
    Moore, Kathleen N.
    Chua, Cynthia C.
    Arkenau, Hendrik-Tobias
    Dukart, Gary
    Harrow, Kim
    Liang, Chris
    ONCOLOGIST, 2019, 24 (04): : 455 - E121
  • [4] A phase I/IIa, open-label, dose-escalation and expansion study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of TJ107 in Chinese patients with advanced solid tumors
    Li, Jin
    Guo, Ye
    Peng, Wei
    Xue, Junli
    Zhao, Wei
    Ge, Xiaoxiao
    Xue, Liqiong
    Tang, Wenbo
    Zhou, Li
    Zhang, Min
    Guo, Bingshi
    Wang, Liping
    Guo, Jiyuan
    Cui, Feifei
    Suo, Haiyun
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [5] Open-label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment
    Saif, Muhammad Wasif
    Rosen, Lee
    Rudek, Michelle A.
    Sun, Weijing
    Shepard, Dale R.
    Becerra, Carlos
    Yamashita, Fumiaki
    Bebeau, Paul
    Winkler, Robert
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (06) : 1239 - 1246
  • [6] A phase 1, open-label, dose-escalation, multicenter study to evaluate the tolerability, safety, pharmacokinetics, and activity of ADCT-301 in patients with relapsed or refractory CD25-positive acute myeloid leukemia.
    Tallman, Martin S.
    Feingold, Jay Marshall
    Spira, Alexander I.
    Rizzieri, David
    Atallah, Ehab L.
    Stock, Wendy
    Jain, Nitin
    Walter, Roland B.
    Chung, Ki Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer
    I M E Desar
    J N H Timmer-Bonte
    D M Burger
    W T A van der Graaf
    C M L van Herpen
    British Journal of Cancer, 2010, 103 : 1637 - 1643
  • [8] A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer
    Desar, I. M. E.
    Timmer-Bonte, J. N. H.
    Burger, D. M.
    van der Graaf, W. T. A.
    van Herpen, C. M. L.
    BRITISH JOURNAL OF CANCER, 2010, 103 (11) : 1637 - 1643
  • [9] Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors
    Minami, Hironobu
    Ando, Yuichi
    Ma, Brigette Buig Yue
    Lee, Jih-Hsiang
    Momota, Hiroyuki
    Fujiwara, Yutaka
    Li, Leung
    Fukino, Koichi
    Ito, Koji
    Tajima, Takeshi
    Mori, Asuka
    Lin, Chia-Chi
    CANCER SCIENCE, 2016, 107 (10) : 1477 - 1483
  • [10] A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors
    Ghamande, Sharad
    Lin, Chia-Chi
    Cho, Daniel C.
    Shapiro, Geoffrey I.
    Kwak, Eunice L.
    Silverman, Michael H.
    Tseng, Yunlong
    Kuo, Min-Wen
    Mach, Wendy B.
    Hsu, Shu-Chi
    Coleman, Teresa
    Yang, James Chih-Hsin
    Cheng, Ann-Lii
    Ghalib, Mohammad H.
    Chuadhary, Imran
    Goel, Sanjay
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (03) : 445 - 451
12345